Focused on novel, nanotechnology-based therapeutics

Oliver Fetzer, Ph.D.
President and Chief Executive Officer

David P. DeMagistris, Ph.D.
Senior Vice President, Pharmaceutical Sciences and Manufacturing

Scott Eliasof, Ph.D.
Senior Director, Research

Scott manages Cerulean’s diverse research team of formulation scientists, synthetic chemists and biologists. Prior to joining Cerulean, Scott was the Director of the Chemical Biology Platform at the Broad Institute of Harvard and the Massachusetts Institute of Technology (MIT), directing a multi-disciplinary team of professional scientists and technicians in the fields of synthetic chemistry, analytical chemistry, high-throughput screening, computational science and software engineering. This interdisciplinary organization is closely affiliated with the laboratory of Stuart Schreiber from Harvard University and is one of the largest and oldest academic screening centers in the country. Prior to joining the Broad Institute, Scott worked at Millennium Pharmaceuticals, where he managed scientific teams in cell biology, molecular biology, neuroscience and bioinformatics for a large-scale genomics-based drug discovery program. Earlier in his career, Scott was at Neurocrine Biosciences, where he played a key role in the exploration of glutamate transporters in the field of stroke and neurological disorders.

Scott received his B.S. from MIT in electrical engineering, Ph.D. from the University of California at Berkeley in neuroscience, and completed his postdoctoral fellowship at the Vollum Institute in Portland, Oregon.

Alexandra Glucksmann, Ph.D.
Senior Vice President, Research and Business Operations

Karen Roberts
Senior Vice President, Finance and Administration

John Ryan, Ph.D., M.D.
Senior Vice President and Chief Medical Officer

Jean Silveri, J.D.
Senior Vice President, General Counsel

Marc Wolfgang
Senior Director, Pharmaceutical Sciences and Manufacturing

Cissy Young, Ph.D.
Director, Strategy and Business Development